Probiotec, The founder led, Over the Counter (OTC) drugs manufacturer has a 200 blue chip customer base and is growing, benefiting from the trend of companies onshoring product sourcing, high regulatory hurdles, and cost cutting.
The group is aiming to achieve in NSW what it did in Victoria via its current warehouse rationalisation. Earnings are under pressure in FY23, but there are positive signs.
Want to see other interesting ASX Healthcare Shares stocks?
Would you like to invest in PBP?
Get access to all our research on PBP + our current best stocks to buy now. 14 days free. No credit card required just enter your email and you're away.
